The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells

Experimental Cell Research

Volumn 316, Issue 20, 2010, Pages 3478-3488

  Moss, Patrice E ^a   Lyles, Besstina E ^a   Stewart, LaMonica V ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Androgen receptor; Androgen independent prostate cancer; PPAR gamma

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; CIGLITAZONE; CYCLIN D1; LUCIFERASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTATE SPECIFIC ANTIGEN; ROSIGLITAZONE; SMALL INTERFERING RNA;

ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 78149406948     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.09.015     Document Type: Article

References (33)

1. American Cancer Society, cancer facts and figures 2009, www.acsevents.org.
2. Westin P., Stattin P., Damber J.E., Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol. 1995, 146:1368-1375.
3. Balk S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002, 60:132-138. discussion 138-139.
4. Burnstein K.L. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J. Cell. Biochem. 2005, 95:657-669.
5. Arnold J.T., Isaacs J.T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr. Relat. Cancer 2002, 9:61-73.
6. Peehl D.M., Feldman D. Interaction of nuclear receptor ligands with the vitamin D signaling pathway in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92:307-315.
7. Smith M.R., Kantoff P.W. Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Invest. New Drugs 2002, 20:195-200.
8. Nwankwo J.O., Robbins M.E. Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot. Essent. Fatty Acids 2001, 64:241-245.
9. Xu Y., Iyengar S., Roberts R.L., Shappell S.B., Peehl D.M. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J. Cell. Physiol. 2003, 196:131-143.
10. Chaffer C.L., Thomas D.M., Thompson E.W., Williams E.D. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006, 6:53.
11. Jiang M., Shappell S.B., Hayward S.W. Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer. J. Cell. Biochem. 2004, 91:513-527.
12. Hisatake J.I., Ikezoe T., Carey M., Holden S., Tomoyasu S., Koeffler H.P. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res. 2000, 60:5494-5498.
13. Yang C.C., Wang Y.C., Wei S., Lin L.F., Chen C.S., Lee C.C., Lin C.C. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. Cancer Res. 2007, 67:3229-3238.
14. Wu H.C., Hsieh J.T., Gleave M.E., Brown N.M., Pathak S., Chung L.W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer 1994, 57:406-412.
15. Segawa Y., Yoshimura R., Hase T., Nakatani T., Wada S., Kawahito Y., Kishimoto T., Sano H. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002, 51:108-116.
16. Qin C., Burghardt R., Smith R., Wormke M., Stewart J., Safe S. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res. 2003, 63:958-964.
17. Lyles B.E., Akinyeke T.O., Moss P.E., Stewart L.V. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 2009, 8:268-277.
18. Yeung F., Li X., Ellett J., Trapman J., Kao C., Chung L.W. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J. Biol. Chem. 2000, 275:40846-40855.
19. Yang C.C., Ku C.Y., Wei S., Shiau C.W., Chen C.S., Pinzone J.J., Ringel M.D. Peroxisome proliferator-activated receptor {gamma}-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol. Pharmacol. 2006.
20. Lee S.E., Jin R.J., Lee S.G., Yoon S.J., Park M.S., Heo D.S., Choi H. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. Anticancer Res. 2000, 20:417-422.
21. Zhang J., Thomas T.Z., Kasper S., Matusik R.J. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000, 141:4698-4710.
22. Knudsen K.E., Cavenee W.K., Arden K.C. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res. 1999, 59:2297-2301.
23. Alt J.R., Cleveland J.L., Hannink M., Diehl J.A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000, 14:3102-3114.
24. Petre C.E., Wetherill Y.B., Danielsen M., Knudsen K.E. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J. Biol. Chem. 2002, 277:2207-2215.
25. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.S., Oh W., Demetri G., Figg W.D., Zhou X.P., Eng C., Spiegelman B.M., Kantoff P.W. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl Acad. Sci. USA 2000, 97:10990-10995.
26. Kubota T., Koshizuka K., Williamson E.A., Asou H., Said J.W., Holden S., Miyoshi I., Koeffler H.P. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998, 58:3344-3352.
27. Yang J., Wei S., Wang D.S., Wang Y.C., Kulp S.K., Chen C.S. Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents. J. Med. Chem. 2008, 51:2100-2107.
28. Wei S., Yang H.C., Chuang H.C., Yang J., Kulp S.K., Lu P.J., Lai M.D., Chen C.S. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J. Biol. Chem. 2008, 283:26759-26770.
29. Liao G., Chen L.Y., Zhang A., Godavarthy A., Xia F., Ghosh J.C., Li H., Chen J.D. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 2003, 278:5052-5061.
30. Shang Y., Myers M., Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 2002, 9:601-610.
31. Yoon H.G., Wong J. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol. Endocrinol. 2006, 20:1048-1060.
32. Dai Y., Ngo D., Forman L.W., Qin D.C., Jacob J., Faller D.V. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol. Endocrinol. 2007, 21:1807-1821.
33. Hodgson M.C., Astapova I., Hollenberg A.N., Balk S.P. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res. 2007, 67:8388-8395.